Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Posts Earnings Results, Beats Expectations By $0.21 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) issued its quarterly earnings data on Wednesday. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.21, FiscalAI reports. The company had revenue of $2.51 million for the quarter, compared to the consensus estimate of $0.40 million.

Armata Pharmaceuticals Stock Performance

Shares of Armata Pharmaceuticals stock traded up $0.06 on Wednesday, hitting $4.31. 126,479 shares of the company’s stock were exchanged, compared to its average volume of 92,798. Armata Pharmaceuticals has a 1 year low of $2.39 and a 1 year high of $16.34. The company has a 50-day simple moving average of $5.77 and a 200-day simple moving average of $8.15. The stock has a market capitalization of $158.22 million, a PE ratio of -0.55 and a beta of 1.30.

Hedge Funds Weigh In On Armata Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ARMP. Millennium Management LLC purchased a new stake in Armata Pharmaceuticals in the fourth quarter worth about $164,000. OMERS ADMINISTRATION Corp bought a new position in shares of Armata Pharmaceuticals during the 4th quarter valued at approximately $177,000. State Street Corp increased its holdings in Armata Pharmaceuticals by 26.1% in the 4th quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after acquiring an additional 10,500 shares in the last quarter. Jane Street Group LLC bought a new stake in Armata Pharmaceuticals during the 4th quarter worth approximately $108,000. Finally, Renaissance Technologies LLC lifted its holdings in Armata Pharmaceuticals by 65.9% during the fourth quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock valued at $430,000 after purchasing an additional 27,200 shares in the last quarter. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Zacks Research raised Armata Pharmaceuticals to a “hold” rating in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Armata Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $15.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.